Kura Oncology
3033 Science Park Road
Suite 220
San Diego
California
92121
United States
Tel: 858-500-8880
Website: http://www.kuraoncology.com/
Email: info@kuraoncology.com
197 articles about Kura Oncology
-
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –
3/8/2022
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.
-
Kura Oncology to Participate in Two Upcoming Investor Conferences - Feb 28, 2022
2/28/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.
-
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported fourth quarter and full year 2021 financial results and provided a corporate update.
-
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
2/17/2022
Kura Oncology, Inc. today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022.
-
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
2/10/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference.
-
Kura Oncology Expands Leadership Team with Key Promotions
2/1/2022
Kura Oncology, Inc. announced the expansion of its leadership team with three promotions: Mollie Leoni, M.D., to Senior Vice President, Clinical Development, Pete De Spain to Senior Vice President, Investor Relations and Corporate Communications, and Tom Doyle to Senior Vice President, Finance and Accounting.
-
The FDA has lifted the partial hold on Kura Oncology's KOMET-001 Phase IB trial on a potential treatment for acute myeloid leukemia.
-
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
1/20/2022
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML).
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
12/16/2021
Kura Oncology, Inc. (Nasdaq: KURA), today announced dose administration for the first patient in KURRENT, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).
-
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
12/13/2021
Kura Oncology, Inc. announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia.
-
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
12/13/2021
Kura Oncology, Inc. (Nasdaq: KURA), today announced final results from a Phase 2 study of tipifarnib as a monotherapy in patients with relapsed or refractory T-cell lymphoma, including an overall response rate (ORR) of 56% and a median overall survival of 32.8 months in heavily pretreated patients with angioimmunoblastic T-cell lymphoma (AITL).
-
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
11/24/2021
Kura Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold.
-
Shares of Kura Oncology have plunged nearly 30% in premarket trading after the FDA placed a partial clinical hold on the company’s Phase Ib leukemia study following the report of a patient's death.
-
Kura Oncology to Participate in Two Upcoming Investor Conferences - Nov 23, 2021
11/23/2021
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences.
-
Kura Oncology Reports Third Quarter 2021 Financial Results
11/4/2021
Kura Oncology, Inc. today reported third quarter 2021 financial results and provided a corporate update.
-
Kura Oncology to Participate in Credit Suisse Healthcare Conference
11/2/2021
Kura Oncology, Inc. today announced its participation in the Credit Suisse 30th Annual Healthcare Conference.
-
Kura Oncology to Report Third Quarter 2021 Financial Results
10/28/2021
Kura Oncology, Inc. today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021.
-
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
10/18/2021
Kura Oncology, Inc. today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary.